AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...
Patients were treated with Tagrisso 80mg once-daily oral tablets until disease progression, unacceptable toxicity or other discontinuation criteria were met. Upon progression, patients in the placebo ...
Tagrisso (osimertinib) is a brand-name oral tablet that’s prescribed for certain adults with non-small cell lung cancer (NSCLC). The cost of the drug with and without insurance can depend on ...
New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer. AstraZeneca has been ...
The change of heart – thanks to an undisclosed price cut off the drug’s £5,770 per 30-tablet bottle list price – means that Tagrisso is now “a cost-effective use of NHS resources” and ...
TAGRISSO® (40mg and 80mg once-daily oral tablets) has been used to treat nearly 800,000 patients across its indications worldwide and AstraZeneca continues to explore TAGRISSO® as a treatment ...
AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer. The regulatory body has approved Tagrisso for the treatment of ...
Tagrisso in the treatment of certain type of lung cancer. The study, called MARIPOSA, showed that at three years of treatment ...
Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback